Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of pharmaceutical composition and application thereof for treating cachexia

A cachexia and drug technology, which is applied in the field of pharmaceutical compositions containing cytarabine and ketorolac, can solve the problems of short duration of effect of cachexia and insignificant effect of weight gain, and achieve amazing therapeutic effect and prolong survival period. , the effect of broad clinical application prospects

Active Publication Date: 2021-02-19
CHANGCHUN NUOSAI BIOTECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the significant side effects of long-term treatments and the shorter duration of their effect on cachexia, they are more suitable for patients with a short expected survival time, and in which the effect of weight gain is not obvious, and the patient's survival is not prolonged

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition and application thereof for treating cachexia
  • A kind of pharmaceutical composition and application thereof for treating cachexia
  • A kind of pharmaceutical composition and application thereof for treating cachexia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] This embodiment provides a pharmaceutical composition. The active ingredients in the pharmaceutical composition are: cytarabine and ketorolac, and the mass ratio of the two is 1.5:1.

Embodiment 2

[0036] This embodiment provides a pharmaceutical composition, the active ingredients in the pharmaceutical composition are: cytarabine and ketorolac trometamol, the mass ratio of the two is 3:1.

Embodiment 3

[0038] This embodiment provides a pharmaceutical composition, the active ingredients in the pharmaceutical composition are: cytarabine hydrochloride and ketorolac, the mass ratio of the two is 3:1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of cytarabine or its analogs and ketorolac or its analogs in treating cachexia, and specifically provides a pharmaceutical composition for treating cachexia. For the first time in the present invention, one or more of cytarabine or its analogues and ketorolac or its analogues are used as the active ingredients of the composition for the treatment of cachexia, which has shown surprising therapeutic effects in animal experiments curative effect. Based on the severity of cachexia, the present invention has broad clinical application prospects.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a pharmaceutical composition containing cytarabine and ketorolac and its application. Background technique [0002] The term cachexia is derived from the Greek words "kakos" and "hexis", which literally means "bad condition". (Cachexia as a major underestimated and unmet medical need: facts and numbers J Cachexia Sarcopenia Muscle (2010) 1:1–5). The main symptoms of cachexia include weight loss, muscle wasting, fatigue and loss of appetite. Cachexia is medically defined as weight loss and physical weakness that cannot be reversed with increased nutrition. Cachexia is common in cancer, AIDS, sepsis, severe trauma, COPD, multiple sclerosis, congestive heart failure, tuberculosis, familial amyloid polyneuropathy, chronic kidney disease, cystic fibrosis, type I diabetes and other progressive Sexual chronic diseases (Biology of Cachexia, J Natl Cancer Inst(1997) 89(23):17...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7068A61K31/407A61P1/14A61P3/00A61P21/00A61P39/00
CPCA61K31/407A61K31/7068A61K2300/00
Inventor 张东旭
Owner CHANGCHUN NUOSAI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com